FDA import enforcement operates along a predictable—but unforgiving—continuum: detention, refusal, and, in repeat cases, import alert placement. Recent FDA data dashboards confirm sustained levels of import refusals and enforcement activity, reflecting the Agency’s continued reliance on data-driven screening and historical compliance patterns.
For importers, the practical issue is not whether this framework exists—but whether entries are resolved early enough to avoid escalation.
Detention: The “Appearance” Standard
FDA may detain a shipment where it “appears” to violate the FD&C Act—a deliberately low threshold.
At this stage:
- FDA issues a Notice of Detention and Hearing
- The importer has a limited window to:
- Submit evidence of compliance
- Provide legal or technical argument
- Propose reconditioning
Because detention is based on appearance—not proof—the outcome turns on whether the importer can rebut that appearance quickly and persuasively.
Refusal: Final Agency Action
If the importer fails to overcome the detention, FDA issues a refusal of admission—its final decision.
Consequences are immediate:
- The shipment must be exported or destroyed within 90 days under CBP supervision
- Additional reconditioning opportunities are limited and often denied after unsuccessful attempts
At this point, the issue is no longer corrective—it is damage mitigation.
Reconditioning: A Narrow Path to Release
Reconditioning remains the principal mechanism to salvage a detained entry.
Typical approaches include:
- Relabeling for misbranding
- Product treatment or segregation for adulteration issues
- Packaging or configuration changes
However:
- FDA evaluates whether the proposal will actually achieve compliance, not merely improve the product
- Inadequate or incomplete proposals are routinely rejected
- Repeated failed attempts materially diminish the likelihood of approval
In practice, reconditioning succeeds only where the plan is specific, verifiable, and aligned with the cited violation.
Import Alerts and DWPE: Escalation Based on History
Where FDA identifies a pattern of violations, it may impose an Import Alert, typically enforced through Detention Without Physical Examination (DWPE).
Under this framework:
- Shipments are detained automatically based on prior violations
- FDA need not inspect or test the specific entry
- The burden shifts entirely to the importer to establish compliance
Once triggered:
- Each entry becomes presumptively noncompliant
- Release requires affirmative evidence (e.g., private lab testing)
- Removal from the alert requires sustained corrective action and supporting data
Recent import alert activity reflects continued reliance on this tool across product categories.
Why Early Resolution Matters
The distinction between detention and refusal is not merely procedural—it is strategic.
Failure to resolve entries at the detention stage can:
- Establish a pattern of refusals, supporting future import alert placement
- Trigger CBP exposure, including storage costs and potential liquidated damages
- Disrupt supply chains through repeat enforcement
Conversely, timely and credible responses can:
- Secure release
- Limit adverse compliance history
- Reduce escalation risk
Key Takeaway
FDA’s import framework is cumulative. Each detained or refused entry contributes to a broader enforcement profile that FDA actively uses in future decisions.
In a system governed by an “appearance of violation” standard and data-driven enforcement, the most effective strategy remains straightforward:
Resolve the entry—fully and credibly—before it becomes part of a larger compliance problem.
For assistance with FDA import detentions, reconditioning proposals, refusals, Liquidated Damages, or Removals from Import Alert, please contact info@garg-law.com.
